Alzheimer’s Disease

Home>Tag:Alzheimer's Disease
Nov 22 2021

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease

By |2021-11-21T20:32:25-05:00November 22nd, 2021|Investor News, News, Press Releases|0 Comments

Halberd Successfully Eradicates TNF-α, a Major Contributing Factor to Alzheimer’s Disease Jackson Center, PA, November 22, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 85% of Tumor Necrosis Factor-alpha (TNF-α) from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through Halberd’s patented extracorporeal process, in combination with its patent-pending laser eradication methodology, TNF-α was eliminated ...

Nov 8 2021

Halberd Files Additional Extracorporeal Patent Application: Treatment of Covid-19 By Exposure to Tuned Radio Frequency Waves

By |2021-11-07T19:56:42-05:00November 8th, 2021|Featured, Investor News, News, Press Releases|0 Comments

Jackson Center, PA, November 8, 2021 – Halberd Corporation (OTC-PINK: "HALB") filed a non-provisional patent application for the extracorporeal treatment of Covid-19 through exposure to radio frequency waves.  Previously, Halberd filed a provisional patent application on this treatment method.  Halberd believes this treatment would be effective against all SARS-CoV-2 variants, and this application preserves Halberd’s ...

Nov 1 2021

Halberd Successfully Eradicates IL-6, a Critical Factor in PTSD, CTE & Alzheimer’s Disease

By |2021-10-31T17:47:07-04:00November 1st, 2021|Featured, Investor News, Medical, News|0 Comments

Elevated levels of IL-6 are believed to be causal factors in PTSD, Chronic Traumatic Encephalopathy, & Alzheimer’s Disease. Jackson Center, PA, November 1, 2021 – Halberd Corporation (OTC PINK:HALB) successfully eradicated 100% of IL-6 from synthetic cerebral spinal fluid (CSF) in preliminary testing.  Through its patented extracorporeal process in combination with its patent-pending laser eradication ...

Oct 25 2021

Halberd Files Provisional Patent on Breakthrough Obesity Treatment

By |2021-10-24T19:32:33-04:00October 25th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 25, 2021 – Halberd Corporation (OTC-PINK: HALB) announces the filing of a provisional patent application with the US Patent and Trademark Office covering their extracorporeal removal from the blood of patients of the various proteins, cytokines and antigens associated with obesity.  Removal of these obesity-related target elements would reduce or eliminate ...

Oct 20 2021

Halberd’s PTSD/Alzheimer’s R&D Reveals Link to Potential Obesity Cure

By |2021-10-19T21:30:49-04:00October 20th, 2021|Featured, Investor News, Medical, News|0 Comments

Jackson Center, PA, October 20, 2021 – Halberd Corporation’s (OTC-PINK: HALB) ongoing research into discovering treatments/cures for PTSD, Alzheimer’s Disease, and other neurodegenerative diseases has led to a potential breakthrough in the battle against obesity.  Research has indicated inflammatory cytokines present in the Cerebral Spinal Fluid (CSF) of neurodegenerative disease patients are also found in ...

Sep 13 2021

Halberd’s Treatment Eradicates Primary Building Block of Alzheimer’s Disease

By |2021-09-12T21:20:30-04:00September 13th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, September 13, 2021 – Halberd Corporation (OTC PINK:HALB) has successfully eradicated the primary building block of neurofibrillary tangles of Alzheimer’s Disease from test fluids in laboratory testing.  Through its patented extracorporeal process in combination with its patent-pending laser eradication process, replication tests conducted at Youngstown State University (YSU) achieved virtually 100% elimination ...

Aug 30 2021

Halberd Corporation Alzheimer’s Disease Treatment Tests Yield Outstanding Results

By |2021-08-29T20:56:56-04:00August 30th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 30, 2021 – Halberd Corp. (OTC PINK:HALB) provided an update on its Alzheimer’s Disease eradication experimentation being conducted at Youngstown State University (YSU) and Arizona State University (ASU).  Following standard scientific methodology, Halberd conducted two rounds of experimentation on Phosphorylated Tau, and the results were so astounding that the researchers want ...

Aug 23 2021

Halberd Files Provisional Patent Application – Furthering Efforts on Alzheimer’s Disease

By |2021-08-22T21:05:51-04:00August 23rd, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 23, 2021 – Halberd Corp. (OTC PINK: "HALB") announced filing a U. S. joint provisional patent application, “Treating Alzheimer’s Disease Utilizing Extracorporeal Radio Frequency.”  The innovation is a result of Halberd’s Sponsored Research conducted at Arizona State University (ASU) and Youngstown State University (YSU).  The provisional patent application covers technology developed ...

Aug 16 2021

Halberd’s Disease Elimination Technology R&D at Youngstown State University (YSU) Draws Attention of CBS Affiliate WKBN

By |2021-08-15T14:11:44-04:00August 16th, 2021|Featured, Investor News, News|0 Comments

Jackson Center, PA, August 16, 2021 – Halberd Corporation’s (OTC-PINK: "HALB") research at Youngstown State University (YSU) caught the attention of Youngstown, OH TV news station, WKBN, a CBS affiliate. The station’s 5:00PM newscast on Friday, August 13, 2021, included a segment on Halberd’s on-going research and testing of its groundbreaking, patent protected technology at ...

Jul 28 2021

Halberd Corporation Successfully Establishes Disease Eradication Proof-of-Concept – “Never Before Accomplished”

By |2021-07-27T17:35:26-04:00July 28th, 2021|Featured, Investor News, News|0 Comments

A Major Step Towards the Elimination of Multiple Infectious Diseases and Possible Treatment for Alzheimer’s Disease/PTSD/CTE Jackson Center, PA, July 28, 2021 – Halberd Corporation (OTC-PINK: "HALB") establishes “proof of concept” taking a major step towards the elimination of multiple infectious diseases, such as, malaria, tuberculosis, sepsis, meningitis, and pandemics, among others, by successfully eliminating ...

Go to Top